Disclosure of interest: Daniel Ullrich: nothing to disclose, Heike Heuer: nothing to disclose, Steffen Mayerl: nothing to disclose, Dagmar Fhrer: nothing to disclose, Christoph Kleinschnitz: nothing to disclose, Friederike Langhauser: nothing to disclose E-Posters - ACUTE ISCHEMIC STROKE MANAGEMENT 01.00 - ACUTE ISCHEMIC STROKE MANAGEMENT - 01.04 - THROMBOLYSIS P2110 - ESOC25-1904 THROMBOLYSIS UTILIZATION AND OUTCOMES IN A PERIPHERAL CENTRAL HOSPITAL COHORT OF SUPRATENTORIAL ISCHEMIC STROKE Jussi Sipil 1,2 , Juha Pkknen 1 , Ayla Mehdiyeva 1,2 , Matti Heikkinen 1,2 , Mohamed Hassan 1,2 , Liisu Balk 1 , Minna Johanna Willman 1 , Albina Kettunen 1 , Anna Saukkonen 1 , Jari Toivanen 1 1 North Karelia Central Hospital, Joensuu, Finland, 2 University of Eastern Finland, Kuopio, Finland Background and Aims: IVT appears underutilised
As researchers have noted, key questions like Will long-term BPC-157 use cause abnormal cell growth or other issues? remain unanswered
Through developing a strong bond with her clients, her commitment is unmistakable
What is B12 And Why Do We Need It
Forma TB-500 (peny T4 vs fragment LKKTETQ) oraz masa czsteczkowa pozostaj do potwierdzenia w COA partii wicym dokumentem tosamoci jest certyfikat analizy
